EMA Refused: Natalizumab Elan Pharma (natalizumab) — Elan Pharma International Ltd.

View source ↗

Summary

The EMA refused the marketing authorization for natalizumab from Elan Pharma International Ltd. for Crohn's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Natalizumab (natalizumab)

Snippet

Status: Refused. Therapeutic area: Crohn Disease. MAH: Elan Pharma International Ltd.. Decision date: 25/01/2008